EuroBiotech: More Articles of Note


> Idorsia partners with Antares to develop a self-administered drug-device product for selatogrel, a P2Y12 receptor antagonist in development in acute myocardial infarction. Release 

> Azeria Therapeutics raised £32 million ($41 million) to advance an estrogen receptor positive breast cancer drug. Syncona provided most of the money. Statement 

> The FDA granted orphan drug designation to ProQR Therapeutics’ QR-1123 in autosomal dominant retinitis pigmentosa. Release 


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

> Galapagos confirmed the interim futility analysis for its idiopathic pulmonary fibrosis phase 3 is likely to take place early in 2021. The target is later than analysts at Jefferies hoped. Webcast

> Zealand Pharma delayed the readout from its phase 3 glepaglutide program to the first half of 2021. The target slipped from late 2020 due to delays in the activation of U.K. and U.S. trial sites. Statement 

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.